Logo image
Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study
Journal article   Open access   Peer reviewed

Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study

Adem T Can, Daniel F Hermens, Megan Dutton, Cyrana C Gallay, Emma Jensen, Monique Jones, Jennifer Scherman, Denise A Beaudequin, Cian Yang, Paul E Schwenn, …
Translational Psychiatry, Vol.11(1), pp.101-101
2021
PMCID: PMC7862447
PMID: 33542187
pdf
Low dose oral ketamine treatment in chronic suicidality- An open-label pilot study505.76 kBDownloadView
Published Version Open Access CC BY V4.0
url
https://doi.org/10.1038/s41398-021-01230-zView
Published Version Open

Abstract

Depression Scientific community Suicide prevention Ketamine Thompson Institute Special Collection
Recently, low-dose ketamine has been proposed as a rapid-acting treatment option for suicidality. The majority of studies to date have utilised intravenous (IV) ketamine, however, this route of administration has limitations. On the other hand, oral ketamine can be administered in a range of settings, which is important in treating suicidality, although studies as to safety and feasibility are lacking. n  = 32 adults (aged 22–72 years; 53% female) with chronic suicidal thoughts participated in the Oral Ketamine Trial on Suicidality (OKTOS), an open-label trial of sub-anaesthetic doses of oral ketamine over 6 weeks. Participants commenced with 0.5 mg/kg of ketamine, which was titrated to a maximum 3.0 mg/kg. Follow-up assessments occurred at 4 weeks after the final dose. The primary outcome measure was the Beck Scale for Suicide Ideation (BSS) and secondary measures included scales for suicidality and depressive symptoms, and measures of functioning and well-being. Mean BSS scores significantly reduced from a high level of suicidal ideation at the pre-ketamine (week 0) timepoint to below the clinical threshold at the post-ketamine (week 6) timepoint. The proportion of participants that achieved clinical improvement within the first 6 weeks was 69%, whereas 50% achieved a significant improvement by the follow-up (week 10) timepoint. Six weeks of oral ketamine treatment in participants with chronic suicidality led to significant reduction in suicidal ideation. The response observed in this study is consistent with IV ketamine trials, suggesting that oral administration is a feasible and tolerable alternative treatment for chronic suicidality.

Details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Web Of Science research areas
Psychiatry

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: SDGs from InCites

Logo image